5243482025-01-012025-03-315243482025-03-315243482024-03-315243482024-04-012025-03-315243482025-01-012025-03-31in-capmkt:OtherExpenses1Member5243482024-04-012025-03-31in-capmkt:OtherExpenses1Member5243482025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243482025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25243482025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35243482024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243482024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25243482024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35243482025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524348AARTIDRUGSNOTLISTEDINE767A01016AARTI DRUGS LIMITEDMain BoardEquity2024-04-012025-03-312025-05-062025-04-29INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2025-05-0612:00:002025-05-0616:00:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated6767600000187000006786300000375140000023130000038640000031350000091600000148800000115180000060748000007115000000711500000103700000-19900000838000000627700000000062770000012800000640500000628600000-915000641300000-756000912700000106.886.88006.886.881. The above results for the Quarter & Year ended 31st March, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 6th May, 2025.  <BR> 2. The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors’ fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)(“Buyback Size”) on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each. <BR> 3. As on March 31, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA. <BR> 4. Company has only one business segment i.e. pharmaceuticals. <BR> 5.Figures for the previous Quarter have been regrouped or rearranged wherever necessary. <BR> 6. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. <BR> <BR> FOR AARTI DRUGS LIMITED <BR> <BR> <BR> Sd/- <BR> Prakash M. Patil <BR> (Chairman, Managing Director&CEO) <BR> DIN: 00005618 <BR> <BR> <BR> Place: Mumbai <BR> Date: 6th May' 20252024-04-012025-03-31AuditedConsolidated23870300000163600000240339000001438300000084340000019460000011210000003587000005578000004457700000219162000002117700000021177000004118000002490000043670000001681000000000016810000001590000016969000001681600000-6150001697200000-30300091270000010018.3518.350018.3518.35Other Expenses1151800000Other Expenses44577000008562500000330180000007150000022410000002033000004274000001236320000047293000000751180000045800000298000007600000150500000774550000010000000080880000013383600000257468000009127000001277730000013690000000340000013693400000284000000000018100000285810000043300000782300000003683700000328240000011800000040434000004161400000214100000765790000066890000042900000008369700000001205340000025746800000FOR AARTI DRUGS LIMITED <BR> <BR> Sd/- <BR> Prakash M. Patil <BR> (Chairman, Managing Director&CEO) <BR> DIN: 00005618 <BR> <BR> Place: Mumbai <BR> Date: 6th May' 202501296000003435000000012300000-270000000-43730000000055780000003720000000025000000000000006429000002760600000-100000-358700000-122000000551200000-20000024458000000000000050000017716000002700000000000000000000010000012200000000-16463000000000731700000000111160000077610000009060000033440000000-821200000-217000000-217000006740000045700000Fair value changes on Investments, net20900000Remeasurement of defined benefit Liabiliy/Assets, net-11200000Foreign currency translation reserve310000012800000Fair value changes on Investments, net20900000Remeasurement of defined benefit Liabiliy/Assets, net-11200000Foreign currency translation reserve620000015900000001280000015900000AuditedtrueGokhale & Sathe, Chartered Accountantstrue2027-02-28